



**For Immediate Release**

**Vaxart to Present Preclinical Data on Oral Quadrivalent Influenza Vaccine  
at ICAAC/ICC 2015**

**SOUTH SAN FRANCISCO, Calif., September 18, 2015** — Vaxart, Inc., a privately held, clinical-stage biotechnology company developing oral recombinant vaccines that are administered in tablet form, announced today that Vaxart Associate Director of Research Ciaran Scallan, PhD, will present preclinical study data at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, California.

Dr. Scallan will report on results of the preclinical data in his poster presentation, “Evaluation of an Oral Annual Quadrivalent Influenza Vaccine Utilizing Novel Adenovirus Vectors in Ferrets” on Saturday, September 19, 2015 from 11:00 a.m. to 1:00 p.m. Pacific Daylight Time in Exhibit Hall F of the San Diego Convention Center.

**About Vaxart**

Vaxart is a privately held, clinical-stage company developing a range of tablet vaccines based on its proprietary oral recombinant vaccines platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, and reduce risk of needle-stick injury associated with injectable vaccines. For more information, please visit [www.vaxart.com](http://www.vaxart.com).

###

**CONTACT:**

Katie Hogan

WCG

415.658.9745

[khogan@wcgworld.com](mailto:khogan@wcgworld.com)